(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 19.91% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.89%.
Rigel Pharmaceuticals's revenue in 2024 is $130,301,000.On average, 4 Wall Street analysts forecast RIGL's revenue for 2024 to be $2,667,345,728, with the lowest RIGL revenue forecast at $2,556,550,158, and the highest RIGL revenue forecast at $2,837,717,891. On average, 4 Wall Street analysts forecast RIGL's revenue for 2025 to be $3,367,062,774, with the lowest RIGL revenue forecast at $3,100,234,947, and the highest RIGL revenue forecast at $3,500,344,724.
In 2026, RIGL is forecast to generate $3,929,873,303 in revenue, with the lowest revenue forecast at $3,766,380,777 and the highest revenue forecast at $4,133,236,047.